ReviewMycopathologia2017
New Antifungal Agents and New Formulations Against Dermatophytes.
Review in Mycopathologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 175 citations in OpenAlex.
- Deciphering the genomic landscape ofMicrobial genomics · 2026Article
- Epidemiological, clinical, and molecular studies on nail disorders in the human population of Punjab, Pakistan.Molecular biology reports · 2026Article
- Rising antifungal resistance inFrontiers in microbiology · 2026Review
- Microbial community structure in tinea corporis and antifungal activity ofFrontiers in cellular and infection microbiology · 2026Article
- DeepADR: multimodal prediction of adverse drug reaction frequency by integrating early-stage drug discovery information via Kolmogorov-Arnold networks.Briefings in bioinformatics · 2025Article
- Antimicrobial effects and mechanisms of hydrogen sulphide against nail pathogens.Scientific reports · 2025Article
- Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.Archives of microbiology · 2025Review
- Biosynthesis of the Paecilomyces marquandii conidial pigment saintopin.Fungal biology and biotechnology · 2025Article
- Case Report: From Misdiagnosis to Accurate Identification: Managing a Case Series ofMicroorganisms · 2025Article
- Targeting fungal lipid synthesis for antifungal drug development and potentiation of contemporary antifungals.npj antimicrobials and resistance · 2025Review
- Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Ufasomes as Topical/Transdermal Drug Delivery System: Structural Components, Preparation Techniques and Therapeutic Application.Current drug delivery · 2025Review
- The Significance of Mono- and Dual-Effective Agents in the Development of New Antifungal Strategies.Chemical biology & drug design · 2025Review
- Comprehensive Review on Tinea Infection Therapies: Allopathic and Herbal Approaches for Dermatophytosis.Recent advances in anti-infective drug discovery · 2025Review
- Kerion-like lesions following an autoinoculation event in patient with chronic onychomycosis - Case report.Medical mycology case reports · 2024Article
- Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced byPharmaceutics · 2024Article
- Modeling, the Optimization of the Composition of Emulgels with Ciclopirox Olamine, and Quality Assessment.Polymers · 2024Article
- Bisphosphonates synergistically enhance the antifungal activity of azoles in dermatophytes and other pathogenic molds.mSphere · 2024Article
- Tinea corporis intrafamilial infection in pets due to Microsporum canis.Revista do Instituto de Medicina Tropical de Sao Paulo · 2024Article
- Membranolytic Activity Profile of Nonyl 3,4-Dihydroxybenzoate: A New Anti-Biofilm Compound for the Treatment of Dermatophytosis.Pharmaceutics · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A variety of oral and topical antifungal agents are available for the treatment of superficial fungal infections caused by dermatophytes. This review builds on the antifungal therapy update published in this journal for the first special issue on Dermatophytosis (Gupta and Cooper 2008;166:353-67). Since 2008, there have not been additions to the oral antifungal armamentarium, with terbinafine, itraconazole, and fluconazole still in widespread use, albeit for generally more severe or recalcitrant infections. Griseofulvin is used in the treatment of tinea capitis. Oral ketoconazole has fallen out of favor in many jurisdictions due to risks of hepatotoxicity. Topical antifungals, applied once or twice daily, are the primary treatment for tinea pedis, tinea corporis/tinea cruris, and mild cases of tinea unguium. Newer topical antifungal agents introduced include the azoles, efinaconazole, luliconazole, and sertaconazole, and the oxaborole, tavaborole. Research is focused on developing formulations of existing topical antifungals that utilize novel delivery systems in order to enhance treatment efficacy and compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.